QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens
February 18 2019 - 4:05PM
Business Wire
Developing Sample to Insight solutions to
accelerate research on growing public health threat
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced a broad agreement with Ares Genetics, a subsidiary of
Curetis N.V. (Euronext: CURE), to develop innovative bioinformatics
and assay solutions to accelerate research targeting the growing
global health challenges posed by antibiotic-resistant
bacteria.
QIAGEN has acquired an exclusive license to leverage Ares
Genetics’ proprietary antimicrobial resistance database, ARESdb, as
well as bioinformatics tools and workflows from the ARES Technology
Platform, AREStools, in QIAGEN’s bioinformatics products and
services for researchers. QIAGEN also obtained a non-exclusive
worldwide license to develop and commercialize molecular research
assays using ARESdb content with QIAGEN next-generation sequencing
(NGS) and polymerase chain reaction (PCR) solutions. Powered by
artificial intelligence, ARESdb is likely the most comprehensive,
global and continuously updated proprietary knowledge base on
genetic antibiotic resistance markers and their diagnostic
relevance.
“With QIAGEN as a prime supplier of industry-leading
applications for the analysis and interpretation of biological
data, we are well positioned to make ARESdb a key resource for
cutting-edge research in the pressing healthcare issue of
antimicrobial resistance,” said Dr. Andreas Posch, Managing
Director and CEO of Ares Genetics. “This partnership has the
potential to greatly facilitate our engagement with the public
health and AMR research communities in the further development and
expansion of ARESdb, our database that is also core to the
NGS-based diagnostic solutions currently developed by Ares
Genetics."
“Antibiotic-resistant diseases are an urgent threat to public
health, as resistance undermines the effective prevention and
treatment of an ever-increasing range of infections. This global
problem cries out for molecular insights that can lead to new
understanding and therapeutic approaches. Partnering with Ares
Genetics to leverage their genomic content with QIAGEN’s expertise
in bioinformatics, NGS and PCR technologies, we will expand our
portfolio of solutions to help the global community fight these
infections,” said Jonathan Sheldon, Senior Vice President and head
of QIAGEN Bioinformatics. QIAGEN is committed to creating
best-in-class Sample to Insight solutions that help combat the
global crisis in antibiotic resistant pathogens. The collaboration
with ARES builds on an already broad portfolio for infectious
disease research tools and adds to other AMR-related initiatives.
QIAGEN will leverage the AMR database from Ares Genetics with its
expertise in bioinformatics, assays and services, enabling the
research community to accelerate the fight against AMR."
Antimicrobial resistance causes an estimated 700,000 deaths a
year, and the toll is expected to grow. A lack of diagnostic tools
and reporting makes the global impact difficult to quantify, but a
recent study predicted deaths will rise to 10 million a year by
2050 if indiscriminate use of antibiotics continues, driving the
growth of resistance. Already, antimicrobial resistance is making
treatment difficult for a growing number of patients affected by
resistant strains of pneumonia and food-borne pathogens.
The collaboration with Ares Genetics builds on QIAGEN’s broad
portfolio for infectious disease research. QIAGEN will integrate
the ARESdb content with its CLC Genomics Workbench and build a
Software-as-a-Service portal providing standardized analysis for
research and enabling flexible design of assays. Together with
QIAGEN’s current sample preparation solutions, GeneGlobe portal and
dedicated bioinformatics solutions, ARESdb will expand QIAGEN’s
market-leading Sample to Insight offering of workflows for research
into antimicrobial resistance. QIAGEN solutions support basic and
clinical research on a range of bacterial infections, including
healthcare-associated and community-acquired infections.
Financial details of the partnership were not disclosed.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of December
31, 2018, QIAGEN employed approximately 5,000 people in over 35
locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, launches, regulatory submissions,
collaborations, markets, strategy, taxes or operating results,
including without limitation its expected sales, adjusted net sales
and adjusted diluted earnings per share results, are
forward-looking, such statements are based on current expectations
and assumptions that involve a number of uncertainties and risks.
Such uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics); variability of operating
results and allocations between customer classes; the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses; and the other factors discussed under the heading “Risk
Factors” contained in Item 3 of our most recent Annual Report on
Form 20-F. For further information, please refer to the discussions
in reports that QIAGEN has filed with, or furnished to, the U.S.
Securities and Exchange Commission (SEC).
###
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190218005263/en/
QIAGENInvestor RelationsJohn Gilardi+49 2103 29
11711Sarah Fakih+49 2103 29 11711e-mail: ir@QIAGEN.com
Public RelationsThomas Theuringer+49 2103 29 11826Robert
Reitze+49 2103 29 11676e-mail: pr@QIAGEN.com
7.5% Sequins Linked TO Iac/Interactive Common Stock (AMEX:QIA)
Historical Stock Chart
From Apr 2024 to May 2024
7.5% Sequins Linked TO Iac/Interactive Common Stock (AMEX:QIA)
Historical Stock Chart
From May 2023 to May 2024